MAPKs’ status at early stages of renal carcinogenesis and tumors induced by ferric nitrilotriacetate

Molecular and Cellular Biochemistry

Volumn 404, Issue 1-2, 2015, Pages 161-170

  Aguilar Alonso, Francisco A ^a   Solano, José D ^a   Vargas Olvera, Chabetty Y ^a   Pacheco Bernal, Ignacio ^a   Pariente Pérez, Telma O ^a   Ibarra Rubio, María Elena ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Carcinogenesis; Ferric nitrilotriacetate; MAPK; Renal cell carcinoma

Indexed keywords

CARCINOGEN; JANUS KINASE 1; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRILOTRIACETATE IRON; FERRIC ION; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NITRILOTRIACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DENSITOMETRY; GENE OVEREXPRESSION; KIDNEY CARCINOMA; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; TISSUE HOMOGENATE; TREATMENT DURATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY TUMOR; PATHOLOGY;

ANIMALS; CARCINOGENESIS; CARCINOGENS; CARCINOMA, RENAL CELL; FERRIC COMPOUNDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRILOTRIACETIC ACID; RATS;

EID: 84941743115     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2375-5     Document Type: Article

References (70)

1. Vasudev NS, Selby PJ, Banks RE (2012) Renal cancer biomarkers: the promise of personalized care. BMC Med 27(10):112
2. Okada S, Midorikawa O (1982) Induction of the rat renal adenocarcinoma by Fe-nitrilotriacetate (Fe-NTA). Jpn Arch Intern Med 29:485–491
3. Ebina Y, Okada S, Hamasaki S, Ogino F, Li JL, Midorikawa O (1986) Nephrotoxicity and renal cell carcinoma after use of iron and aluminum-nitrilotriacetate complexes in rats. J Natl Cancer Inst 76:107–113
4. Li JL, Okada S, Hamazaki S, Ebina Y, Midorikawa O (1987) Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res 47:1867–1869
5. Athar M, Iqbal M (1998) Ferric nitrilotriacetate promotes N-diethylnitrosamine-induced renal tumorigenesis in the rat: implications for the involvement of oxidative stress. Carcinogenesis 19:1133–1139
6. Jahangir T, Sultana S (2006) Modulatory effects of Pluchea lanceolata against chemically induced oxidative damage, hyperproliferation and two-stage renal carcinogenesis in Wistar rats. Mol Cell Biochem 291:175–185
7. Vargas-Olvera CY, Sánchez-González DJ, Solano JD, Aguilar-Alonso FA, Montalvo-Muñoz F, Martínez-Martínez CM, Medina-Campos ON, Ibarra-Rubio ME (2012) Characterization of N-diethylnitrosamine-initiated and ferric nitrilotriacetate-promoted renal cell carcinoma experimental model and effect of a tamarind seed extract against acute nephrotoxicity and carcinogenesis. Mol Cell Biochem 369:105–117
8. Hiroyasu M, Ozeki M, Kohda H, Echizenya M, Tanaka T, Hiai H, Toyokuni S (2002) Specific allelic loss of p16 (INK4A) tumor suppressor gene after weeks of iron-mediated oxidative damage during rat renal carcinogenesis. Am J Pathol 160:419–424
9. Taniai E, Hayashi H, Yafune A, Watanabe M, Akane H, Suzuki K, Mitsumori K, Shibutani M (2012) Cellular distribution of cell cycle-related molecules in the renal tubules of rats treated with renal carcinogens for 28 days: relationship between cell cycle aberration and carcinogenesis. Arch 86:1453–1464
10. Bahnemann R, Leibold E, Kittel B, Mellert W, Jäckh R (1998) Different patterns of kidney toxicity after subacute administration of Na-nitrilotriacetic acid and Fe-nitrilotriacetic acid to Wistar rats. Toxicol Sci 46:166–175
11. Umemura T, Sai K, Takagi A, Hasegawa R, Kurokawa Y (1990) Oxidative DNA damage, lipid peroxidation and nephrotoxicity induced in the rat kidney after ferric nitrilotriacetate administration. Cancer Lett 54:95–100
12. Toyokuni S, Uchida K, Okamoto K (1994) Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Natl Acad Sci 91:2616–2620
13. Chen L, Wang Y, Kairaitis LK, Wang Y, Zhang BH, Harris DC (2001) Molecular mechanisms by which iron induces nitric oxide synthesis in cultured proximal tubule cells. Exp Nephrol 9:198–204
14. Gago-Dominguez M, Castelao JE (2006) Lipid peroxidation and renal cell carcinoma: further supportive evidence and new mechanistic insights. Free Radic Biol Med 40:721–733
15. Bosetti C, Scotti L, Maso LD, Talamini R, Montella M, Negri E, Ramazzotti V, Franceschi S, La Vecchia C (2007) Micronutrients and the risk of renal cell cancer: a case-control study from Italy. Int J Cancer 120:892–896
16. Bosetti C, Rossi M, McLaughlin JK, Negri E, Talamini R, Lagiou P, Montella M, Ramazzotti V, Franceschi S, LaVecchia C (2007) Flavonoids and the risk of renal cell carcinoma. Cancer Epidemiol Biomark Prev 16:98–101
17. Kim EK, Choi EJ (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802:396–405
18. Peti W, Page R (2013) Molecular basis of MAP kinase regulation. Protein Sci 22:1698–1710
19. Yang SH, Sharrocks AD, Whitmarsh AJ (2013) MAP kinase signalling cascades and transcriptional regulation. Gene 513:1–13
20. Cuadrado A, Nebreda AR (2010) Mechanisms and functions of p38 MAPK signalling. Biochem J 429:403–417
21. Han J, Sun P (2007) The pathways to tumor suppression via route p38. Trends Biochem Sci 32:364–371
22. Hui L, Bakiri L, Stepniak E, Wagner EF (2007) p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle 6:2429–2433
23. Koul HK, Pal M, Koul S (2013) Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer 4:342–359
24. Tang J, Qi X, Mercola D, Han J, Chen G (2005) Essential role of p38gamma in K-Ras transformation independent of phosphorylation. J Biol Chem 280:23910–23917
25. Samaras V, Tsopanomichalou M, Stamatelli A, Arnaoutoglou C, Samaras E, Arnaoutoglou M, Poulias H, Barbatis C (2009) Is there any potential link among caspase-8, p-p38 MAPK and bcl-2 in clear cell renal cell carcinomas? A comparative immunohistochemical analysis with clinical connotations. Diagn Pathol 4:7
26. Ozbek E, Aliskan T, Otunctemur A, Calik G, Cakir S, Dursun M, Somay A (2012) Comparison of tumor grade and stage with nuclear factor kappa b and p38 mitogene activated protein kinase expressions in renal cell cancer. Arch Ital Urol Androl 84:53–60
27. Ambrose M, Ryan A, O’Sullivan GC, Dunne C, Barry OP (2006) Induction of apoptosis in renal cell carcinoma by reactive oxygen species: involvement of extracellular signal-regulated kinase 1/2, p38delta/gamma, cyclooxygenase-2 down-regulation, and translocation of apoptosis-inducing factor. Mol Pharmacol 69:1879–1890
28. Sabapathy K, Wagner EF (2004) JNK2: a negative regulator of cellular proliferation. Cell Cycle 3:1520–1523
29. Bubici C, Papa S (2014) JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol 171:24–37
30. Mizuno R, Oya M, Shiomi T, Marumo K, Okada Y, Murai M (2004) Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells. J Urol 172:723–727
31. Takano Y, Iwata H, Yano Y, Miyazawa M, Virgona N, Sato H, Ueno K, Yano T (2010) Up-regulation of connexin 32 gene by 5-aza-2′-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling. Biochem Pharmacol 80:463–470
32. Xu M, Hong M, Xie H (2013) Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation. Nan Fang Yi Ke Da Xue Xue Bao 33:1409–1415
33. An J, Liu H, Magyar CE, Guo Y, Veena MS, Srivatsan ES, Huang J, Rettig MB (2013) Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma. Cancer Res 73:1374–1385
34. Bogoyevitch MA, Court NW (2004) Counting on mitogen-activated protein kinases–ERKs 3, 4, 5, 6, 7 and 8. Cell Signal 16:1345–1354
35. Deschênes-Simard X, Kottakis F, Meloche S, Ferbeyre G (2014) ERKs in cancer: friends or foes? Cancer Res 74:412–419
36. Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y, Kawaichi M, Kohno M, Yoshida O (1995) Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55:4182–4187
37. Lee HJ, Kim DI, Kang GH, Kwak C, Ku JH, Moon KC (2009) Phosphorylation of ERK1/2 and prognosis of clear cell renal cell carcinoma. Urology 73:394–399
38. Campbell L, Nuttall R, Griffiths D, Gumbleton M (2009) Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma. Cancer 115:3457–3467
39. Marin-Kuan M, Nestler S, Verguet C, Bezençon C, Piguet D, Delatour T, Mantle P, Cavin C, Schilter B (2007) MAPK-ERK activation in kidney of male rats chronically fed ochratoxin A at a dose causing a significant incidence of renal carcinoma. Toxicol Appl Pharmacol 224:174–181
40. Cohen JD, Gard JM, Nagle RB, Dietrich JD, Monks TJ, Lau SS (2011) ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. Toxicol Sci 124:75–87
41. Salinas-Sánchez AS, Giménez-Bachs JM, Serrano-Oviedo L, Nam Cha S, Sánchez-Prieto R (2012) Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma. Actas Urol Esp 36:99–103
42. Nogueira M, Kim HL (2008) Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol 26:113–124
43. Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-Beltran A, Martignoni G, Rini BI, Kutikov A (2014) Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. doi:10.1016/j.eururo.2014.04.029
44. Omori S, Hida M, Ishikura K, Kuramochi S, Awazu M (2000) Expression of mitogen-activated protein kinase family in rat renal development. Kidney Int 58:27–37
45. Omori S, Fukuzawa R, Hida M, Awazu M (2002) Expression of mitogen-activated protein kinases in human renal dysplasia. Kidney Int 61:899–906
46. Liu YT, Shang D, Akatsuka S, Ohara H, Dutta KK, Mizushima K, Naito Y, Yoshikawa T, Izumiya M, Abe K, Nakagama H, Noguchi N, Toyokuni S (2007) Chronic oxidative stress causes amplification and overexpression of ptprz1 protein tyrosine phosphatase to activate beta-catenin pathway. Am J Pathol 171:1978–1988
47. Rehman MU, Tahir M, Khan AQ, Khan R, Lateef A, Oday-O-Hamiza Qamar W, Ali F, Sultana S (2013) Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: plausible role of NF-κB. Toxicol Lett 216:146–158
48. Fitzsimmons BL, Zattoni M, Svensson CI, Steinauer J, Hua XY, Yaksh TL (2010) Role of spinal p38alpha and beta MAPK in inflammatory hyperalgesia and spinal COX-2 expression. NeuroReport 21:313–317
49. Kim MK, Maeng YI, Sung WJ, Oh HK, Park JB, Yoon GS, Cho CH, Park KK (2013) The differential expression of TGF-β1, ILK and wnt signaling inducing epithelial to mesenchymal transition in human renal fibrogenesis: an immunohistochemical study. Int J Clin Exp Pathol 6:1747–1758
50. Hou SW, Zhi HY, Pohl N, Loesch M, Qi XM, Li RS, Basir Z, Chen G (2010) PTPH1 dephosphorylates and cooperates with p38gamma MAPK to increase ras oncogenesis through PDZ-mediated interaction. Cancer Res 70:2901–2910
51. Rosenthal DT, Iyer H, Escudero S, Bao L, Wu Z, Ventura AC, Kleer CG, Arruda EM, Garikipati K, Merajver SD (2011) p38γ promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior. Cancer Res 71:6338–6349
52. Yang K, Liu Y, Liu Z, Liu J, Liu X, Chen X, Li C, Zeng Y (2013) p38γ overexpression in gliomas and its role in proliferation and apoptosis. Sci Rep 3:2089
53. Qi X, Pohl NM, Loesch M, Hou S, Li R, Qin JZ, Cuenda A, Chen G (2007) p38alpha antagonizes p38gamma activity through c-Jun-dependent ubiquitin-proteasome pathways in regulating Ras transformation and stress response. J Biol Chem 282:31398–313408
54. Loesch M, Zhi HY, Hou SW, Qi XM, Li RS, Basir Z, Iftner T, Cuenda A, Chen G (2010) p38gamma MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. J Biol Chem 285:15149–15158
55. Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF (2008) Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest 118:3943–3953
56. Mitra S, Lee JS, Cantrell M, Van den Berg CL (2011) c-Jun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8). J Biol Chem 286:15287–15297
57. Ishizawa J, Yoshida S, Oya M, Mizuno R, Shinojima T, Marumo K, Murai M (2004) Inhibition of the ubiquitin-proteasome pathway activates stress kinases and induces apoptosis in renal cancer cells. Int J Oncol 25:697–702
58. Ou YC, Yang CR, Cheng CL, Raung SL, Hung YY, Chen CJ (2007) Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Eur J Pharmacol 563:49–60
59. Liang YY, Zheng LS, Wu YZ, Peng LX, Cao Y, Cao X, Xie P, Huang BJ, Qian CN (2014) RASSF6 promotes p21(Cip1/Waf1)-dependent cell cycle arrest and apoptosis through activation of the JNK/SAPK pathway in clear cell renal cell carcinoma. Cell Cycle 13:1440–1449
60. Yoon HS, Monks TJ, Everitt JI, Walker CL, Lau SS (2002) Cell proliferation is insufficient, but loss of tuberin is necessary, for chemically induced nephrocarcinogenicity. Am J Physiol Renal Physiol 283:F262–F270
61. Vaidya VS, Shankar K, Lock EA, Dixon D, Mehendale HM (2003) Molecular mechanisms of renal tissue repair in survival from acute renal tubule necrosis: role of ERK1/2 pathway. Toxicol Pathol 31:604–618
62. Aguirre Ghiso JA, Kovalski K, Ossowski L (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147:89–104
63. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L (2001) Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12:863–879
64. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L (2003) ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 63:1684–1695
65. Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK (2004) Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 64:7336–7345
66. Omori S, Hida M, Fujita H, Takahashi H, Tanimura S, Kohno M, Awazu M (2006) Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 17:1604–1614
67. Omori S, Kitagawa H, Koike J, Fujita H, Hida M, Pringle KC, Awazu M (2008) Activated extracellular signal-regulated kinase correlates with cyst formation and transforming growth factor-beta expression in fetal obstructive uropathy. Kidney Int 73:1031–1037
68. Puisieux A, Brabletz T, Caramel J (2014) Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 16:488–494
69. Ansar S, Iqbal M, Athar M (1999) Nordihydroguaiaretic acid is a potent inhibitor of ferric-nitrilotriacetate-mediated hepatic and renal toxicity, and renal tumour promotion, in mice. Carcinogenesis 20:599–606
70. Court NW, dos Remedios CG, Cordell J, Bogoyevitch MA (2002) Cardiac expression and subcellular localization of the p38 mitogen-activated protein kinase member, stress-activated protein kinase-3 (SAPK3). J Mol Cell Cardiol 34:413–426